Imaging in neuro-oncology

Imaging plays several key roles in managing brain tumors, including diagnosis, prognosis, and treatment response assessment. Ongoing challenges remain as new therapies emerge and there are urgent needs to find accurate and clinically feasible methods to noninvasively evaluate brain tumors before and after treatment. This review aims to provide an overview of several advanced imaging modalities including magnetic resonance imaging and positron emission tomography (PET), including advances in new PET agents, and summarize several key areas of their applications, including improving the accuracy of diagnosis and addressing the challenging clinical problems such as evaluation of pseudoprogression and anti-angiogenic therapy, and rising challenges of imaging with immunotherapy.

• Publication year

  2018

• Venue

  Therapeutic Advances in Neurological Disorders

• Publication date

  2018-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1756286418759865PMID 29511385PMCID 5833173
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic value of relative cerebral blood volume in patients with recurrent glioblastoma multiforme treated with bevacizumab.

  2019cited by this paper
• Diagnostic value of apparent diffusion coefficient in differentiating between high-grade gliomas and brain metastases

  2018cited by this paper
• Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma

  2018cited by this paper
• Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma

  2018cited by this paper
• Radiologic progression of glioblastoma under therapy—an exploratory analysis of AVAglio

  2018cited by this paper
• Static and dynamic 18F–FET PET for the characterization of gliomas defined by IDH and 1p/19q status

  2018cited by this paper
• Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab

  2017cited by this paper
• In Vivo Detection of EGFRvIII in Glioblastoma via Perfusion Magnetic Resonance Imaging Signature Consistent with Deep Peritumoral Infiltration: The ϕ-Index

  2017cited by this paper
• Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas

  2017cited by this paper
• Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging

  2017cited by this paper
• MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.

  2017cited by this paper
• Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials

  2017cited by this paper
• Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients

  2017cited by this paper
• Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab—a report from the BELOB trial

  2017cited by this paper
• Comparison between Glioblastoma and Primary Central Nervous System Lymphoma Using MR Image-based Texture Analysis

  2017cited by this paper
• Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study

  2017cited by this paper
• MRI features predict survival and molecular markers in diffuse lower-grade gliomas

  2017cited by this paper
• Detection of immune responses after immunotherapy in glioblastoma using PET and MRI

  2017cited by this paper
• Radiomic features from the peritumoral brain parenchyma on treatment-naïve multi-parametric MR imaging predict long versus short-term survival in glioblastoma multiforme: Preliminary findings

  2017cited by this paper
• Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging

  2017cited by this paper
• Preoperative grading of supratentorial nonenhancing gliomas by high b-value diffusion-weighted 3 T magnetic resonance imaging

  2017cited by this paper
• Automatic estimation of extent of resection and residual tumor volume of patients with glioblastoma.

  2017cited by this paper
• Tumor Infiltration in Enhancing and Non-Enhancing Parts of Glioblastoma: A Correlation with Histopathology

  2017cited by this paper
• Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.

  2017cited by this paper
• Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps

  2017cited by this paper
• Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma

  2017cited by this paper
• Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study

  2017cited by this paper
• Visualization of heterogeneity and regional grading of gliomas by multiple features using magnetic resonance-based clustered images

  2016cited by this paper
• Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)‐MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab

  2016cited by this paper
• Clinical Evaluation of a Fully-automatic Segmentation Method for Longitudinal Brain Tumor Volumetry

  2016cited by this paper
• Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.

  2016cited by this paper
• The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

  2016cited by this paper
• Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma

  2016cited by this paper
• Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment

  2016cited by this paper
• Identifying spatial imaging biomarkers of glioblastoma multiforme for survival group prediction

  2016cited by this paper
• Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques.

  2016cited by this paper
• Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models.

  2016cited by this paper
• Multiparametric MRI-based differentiation of WHO grade II/III glioma and WHO grade IV glioblastoma

  2016cited by this paper
• Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor.

  2016cited by this paper
• Improve Glioblastoma Multiforme Prognosis Prediction by Using Feature Selection and Multiple Kernel Learning

  2016cited by this paper
• CT radiomic analysis using lymph-node-density profile in correlation to SUV-value for PET/CT based N-Staging

  2016cited by this paper
• Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.

  2016cited by this paper
• 139 Clinically Applicable and Biologically Validated MRI Radiomic Test Method Predicts Glioblastoma Genomic Landscape and Survival.

  2016cited by this paper
• Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.

  2016cited by this paper
• Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases.

  2016cited by this paper
• Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features.

  2016cited by this paper
• Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer.

  2016cited by this paper
• Efficient multi‐scale 3D CNN with fully connected CRF for accurate brain lesion segmentation

  2016cited by this paper
• Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.

  2016cited by this paper
• Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma

  2016cited by this paper
• Automated Segmentation of Hyperintense Regions in FLAIR MRI Using Deep Learning

  2016cited by this paper
• Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response

  2016cited by this paper
• Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.

  2016cited by this paper
• Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine

  2016cited by this paper
• Imaging Surrogates of Infiltration Obtained Via Multiparametric Imaging Pattern Analysis Predict Subsequent Location of Recurrence of Glioblastoma.

  2016cited by this paper
• MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas

  2016cited by this paper
• Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced–MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma

  2016cited by this paper
• MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.

  2016cited by this paper
• ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI

  2016cited by this paper
• Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

  2015cited by this paper
• Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma

  2015cited by this paper
• Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET

  2015cited by this paper
• ASFNR Recommendations for Clinical Performance of MR Dynamic Susceptibility Contrast Perfusion Imaging of the Brain

  2015cited by this paper
• Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

  2015cited by this paper
• Prognostic Significance of Dynamic 18F-FET PET in Newly Diagnosed Astrocytic High-Grade Glioma

  2015cited by this paper
• Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

  2015cited by this paper
• A meta-analysis comparing 18F-FLT PET with 18F-FDG PET for assessment of brain tumor recurrence

  2015cited by this paper
• Prediction of clinical phenotypes in invasive breast carcinomas from the integration of radiomics and genomics data

  2015cited by this paper
• Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI)

  2015cited by this paper
• Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma

  2015cited by this paper
• The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab

  2015cited by this paper
• Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate

  2015cited by this paper
• Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value

  2015cited by this paper
• Fully automatic GBM segmentation in the TCGA-GBM dataset: Prognosis and correlation with VASARI features

  2015cited by this paper
• Principles of T2*‐weighted dynamic susceptibility contrast MRI technique in brain tumor imaging

  2015cited by this paper
• Associating spatial diversity features of radiologically defined tumor habitats with epidermal growth factor receptor driver status and 12-month survival in glioblastoma: methods and preliminary investigation

  2015cited by this paper
• [18F]-fluoro-l-thymidine PET and advanced MRI for preoperative grading of gliomas

  2015cited by this paper
• Clinical proton MR spectroscopy in central nervous system disorders.

  2014cited by this paper
• Pretreatment ADC Histogram Analysis Is a Predictive Imaging Biomarker for Bevacizumab Treatment but Not Chemotherapy in Recurrent Glioblastoma

  2014cited by this paper
• Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma

  2014cited by this paper
• Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

  2014cited by this paper
• Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab

  2014cited by this paper
• Assessment of early therapy response with 18F-FLT PET in glioblastoma multiforme.

  2014cited by this paper
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  2014cited by this paper
• Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.

  2014cited by this paper
• Diagnostic Utility of Diffusion Tensor Imaging in Differentiating Glioblastomas from Brain Metastases

  2014cited by this paper
• Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor.

  2014cited by this paper
• Dynamic 18F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients

  2014cited by this paper
• Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.

  2014cited by this paper
• clinical Proton M r s pectroscopy in central nervous s ystem Disorders 1

  2014cited by this paper
• Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: a systematic review and meta-analysis.

  2014cited by this paper
• Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

  2014cited by this paper
• A randomized trial of bevacizumab for newly diagnosed glioblastoma.

  2014cited by this paper
• Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab

  2014cited by this paper
• Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.

  2013cited by this paper
• Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.

  2013cited by this paper
• Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper

• Artificial intelligence in Glioblastoma Diagnostics: Integrating MRI, histopathology, and molecular profiling.

  2025cites this paper
• The hydrogenation side-reaction in copper-mediated radiofluorination

  2025cites this paper
• Precision medicine in neuro-oncology: The role of nursing in targeted therapies and immunotherapy

  2025cites this paper
• FANCL: Feature-Guided Attention Network with Curriculum Learning for Brain Metastases Segmentation

  2024influential citation
• MRI Characteristics of Primary Brain Tumors and Advanced Diagnostic Imaging Techniques.

  2024cites this paper
• Radiomics and visual analysis for predicting success of transplantation of heterotopic glioblastoma in mice with MRI

  2024cites this paper
• Advances in Neuro-Oncological Imaging: An Update on Diagnostic Approach to Brain Tumors

  2024cites this paper
• The Current Diagnostic Performance of MRI-Based Radiomics for Glioma Grading: A Meta-Analysis.

  2024cites this paper
• A Cognitive Computing Tool for Differential Diagnosis between Metastases and High Grade Gliomas

  2024cites this paper
• A Cognitive Computing Tool for Identification and Classification of Brain Tumors

  2024cites this paper
• Cell-Free miRNAs as Non-Invasive Biomarkers in Brain Tumors

  2023cites this paper
• An Approach in Brain Tumor Classification: The Development of a New Convolutional Neural Network Model

  2023cites this paper
• Survey of neuroimaging in neurological surgery, current state, and emerging research

  2023cites this paper
• A reliable and automated synthesis of 6-[18F]fluoro-L-DOPA and the clinical application on the imaging of congenital hyperinsulinism of infants

  2022cites this paper
• Principles of Lung Cancer Metastasis to Brain

  2022cites this paper
• Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas

  2022cites this paper
• Update on the Use of PET/MRI Contrast Agents and Tracers in Brain Oncology: A Systematic Review

  2022cites this paper
• Role of Molecular Imaging with PET/MR Imaging in the Diagnosis and Management of Brain Tumors.

  2022cites this paper
• PET-CT in Clinical Adult Oncology—V. Head and Neck and Neuro Oncology

  2022cites this paper
• Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors

  2022cites this paper
• Multimodality MRI-based radiomics approach to predict the posttreatment response of lung cancer brain metastases to gamma knife radiosurgery

  2022cites this paper
• Marcadores Moleculares y Biomarcadores de Imagen. Importancia en el Avance Terapéutico de los Tumores Cerebrales Intraaxiales

  2021cites this paper
• Pseudoprogression versus true progression in glioblastoma patients: a multiapproach literature review. Part 2 - Radiological features and metric markers.

  2021cites this paper
• A Critical Review of PET Tracers Used for Brain Tumor Imaging.

  2021cites this paper
• Current Pharmaceutical Biotechnology

  2021cites this paper
• Physiological Imaging Methods for Evaluating Response to Immunotherapies in Glioblastomas

  2021cites this paper
• Comparison of Amino Acid PET to Advanced and Emerging MRI Techniques for Neurooncology Imaging: A Systematic Review of the Recent Studies

  2021cites this paper
• Circulating micro-RNAs as biomarkers in brain tumors

  2021cites this paper
• Reassessing the Role of Brain Tumor Biopsy in the Era of Advanced Surgical, Molecular, and Imaging Techniques—A Single-Center Experience with Long-Term Follow-Up

  2021cites this paper
• Case Series: Glioblastoma Highlighting the Eye Care Provider's Role

  2021cites this paper
• Evaluating potential of multi-parametric MRI using co-registered histology: Application to a mouse model of glioblastoma.

  2021cites this paper
• The feasibility of MRI texture analysis in distinguishing glioblastoma, anaplastic astrocytoma and anaplastic oligodendroglioma

  2021cites this paper
• Accuracy of Magnetic Resonance Spectroscopy in Discrimination of Neoplastic and Non-Neoplastic Brain Lesions

  2021cites this paper
• A Modern View of the Use of Positron Emission Tomography with 18F-fluoroethyltyrosine Combined with Computed Tomography in Neurooncology

  2020cites this paper
• Take Advantage of Glutamine Anaplerosis, the Kernel of the Metabolic Rewiring in Malignant Gliomas

  2020cites this paper
• Ipilimumab: an investigational immunotherapy for glioblastoma

  2020cites this paper
• Современный взгляд на использование в нейроонкологии позитронной эмиссионной томографии с 18 -фторэтилтирозином, совмещенной с компьютерной томографией

  2020cites this paper
• Copper-mediated late-stage radiofluorination: five years of impact on preclinical and clinical PET imaging

  2020cites this paper
• Reference values of physiological 18F-FET uptake: Implications for brain tumor discrimination

  2020cites this paper
• Synthesis of high-molar-activity [18F]6-fluoro-l-DOPA suitable for human use via Cu-mediated fluorination of a BPin precursor

  2020cites this paper
• Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors

  2020cites this paper
• Advanced magnetic resonance imaging to support clinical drug development for malignant glioma.

  2020cites this paper
• PET imaging of medulloblastoma with an 18F-labeled tryptophan analogue in a transgenic mouse model

  2020cites this paper
• On the Assessment of Image Inhomogeneity Using T2 Magnetic Resonance Imaging in Head Phantom for Radiotherapy Treatment Planning: Preliminary Study

  2020cites this paper
• Radionuclide imaging of central nervous system

  2019cites this paper
• Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas.

  2019cites this paper
• Deep-learning-based Detection and Segmentation-assisted Management on Brain Metastases.

  2019cites this paper
• Brain immunology and immunotherapy in brain tumours

  2019cites this paper
• An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care.

  2019cites this paper
• Conventional MRI radiomics in patients with suspected early- or pseudo-progression

  2019cites this paper
• Radiopathomics: Integration of radiographic and histologic characteristics for prognostication in glioblastoma

  2019cites this paper
• Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology

  2019cites this paper
• Radiological Imaging in Brain Disorders: An Overview

  2019cites this paper
• Radiomics derived from amino-acid PET and conventional MRI in patients with high-grade gliomas.

  2018cites this paper
• Development of a graphic interface for the three-dimensional semiautomatic glioblastoma segmentation based on magnetic resonance images

  2018cites this paper
• Extraction et analyse de biomarqueurs issus des imageries TEP et IRM pour l'amélioration de la planification de traitement en radiothérapie

  2018cites this paper
• Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod

  2018cites this paper
• Multimodal approach to the evaluation of diffuse neuroinflammation in multiple sclerosis using positron emission tomography and diffusion tensor imaging

  2018cites this paper
• Preoperative grading of supratentorial nonenhancing gliomas by high b-value diffusion-weighted 3 T magnetic resonance imaging

  2017cites this paper
• Evaluating potential of multi-parametric MRI using co-1 registered histology: Application to a mouse model of 2 Glioblastoma. 3

  year unknowninfluential citation